Shanghai Sanyou Medical Co., Ltd. (688085)

Individual Stock Analysis Report | Industry: Medical Devices (Orthopedic Implant Consumables) | Report Date: September 13, 2026 | As of the close on September 11, 2026; moving averages, MACD, RSI, and Bollinger Bands reflect the latest accessible technical module data on the page. Some indicators are not explicitly labeled with independent calculation timestamps on the page and cannot be fully regarded as recalculated values after the September 11 close.

This report is automatically compiled and generated by AI based on publicly available information, for reference only, and does not constitute investment advice.

1. Core Summary

Sanyou Medical achieved operating revenue of RMB 274 million in H1 2026, up 9.71% year-over-year, but net profit attributable to parent was RMB 27.752 million, down 24.18% year-over-year, and non-GAAP net profit attributable to parent was RMB 14.2496 million, down 45.24% year-over-year. The profit decline was mainly affected by share-based payment expenses of RMB 15.6076 million, asset and credit impairment losses of RMB 12.9583 million, and exchange losses of RMB 6.1855 million; under the company's and brokerages' adjusted basis excluding these factors, adjusted net profit attributable to parent was approximately RMB 62.5034 million, up 41.58% year-over-year, but this metric is not the net profit attributable to parent under the company's accounting standards.

The company's core revenue still comes from spinal implant consumables, with revenue of RMB 309 million in the reporting period, accounting for 68.30% of total operating revenue, with a gross margin of 66.40%; overall gross margin in H1 2026 rose to 75.00%. Against the backdrop of full implementation of spinal volume-based procurement and low terminal prices, the company's revenue growth relies more on new spinal products, ultrasonic bone scalpels, overseas business, and product mix improvement. In fiscal year 2025, the company's operating revenue was RMB 543 million, up 19.66% year-over-year, net profit attributable to parent was approximately RMB 63.2895 million, up 451.85% year-over-year, and non-GAAP net profit attributable to parent was RMB 49.6671 million, achieving a turnaround from losses.

The second growth curve is gradually taking shape: the company has achieved 100% ownership of Shuimu Tianpeng through acquisition. In H1 2026, Shuimu Tianpeng's standalone consolidated revenue was RMB 74.5064 million and non-GAAP net profit attributable to parent was RMB 25.9048 million; Implanet France's revenue was EUR 7.134 million, up 22.81% year-over-year, of which U.S. market revenue grew 54.42%. In addition, Implanet completed the first installation of a multi-arm spinal surgical robot in Europe, and the SWINGO-3D lumbar interbody fusion system received U.S. FDA 510(k) clearance.

As of September 11, 2026, the company's stock closed at RMB 12.81, down approximately 6.5% over the past 5 trading days, below MA5, MA10, MA20, and the lower Bollinger Band, with MACD below the zero line, indicating a weak short-term technical pattern; over the past 10 trading days, institutional funds recorded a cumulative net outflow of approximately RMB 17.36 million. On September 11, turnover was approximately RMB 20.5 million with a turnover rate of approximately 0.46%. According to consensus estimates, the company's net profit attributable to parent for 2026–2028 is approximately RMB 108 million, RMB 168 million, and RMB 227 million, respectively, but the number of forecasting institutions is relatively small, and the corresponding PE ratios based on the trailing six-month average price are 42.55x, 27.37x, and 20.20x, respectively, meaning earnings delivery and valuation digestion still require monitoring.

2. Company Overview

2.1 Basic Information

2.2 Main Business and Product Layout

• Spinal implant consumables: Operating revenue of RMB 309.0714 million in the reporting period, accounting for 68.30% of total operating revenue, operating cost of RMB 103.8342 million, gross margin of 66.40%
• Ultrasonic bone scalpel (active device): Deployed through the acquisition of Shuimu Tianpeng, described as a well-known domestic ultrasonic bone scalpel company and a domestic leader in ultrasonic bone scalpels, with business continuing to grow rapidly
• Spinal surgical robot: Subsidiary Implanet completed the first installation of a multi-arm spinal surgical robot in Europe, representing an innovative pipeline and internationalization direction
• Overseas business: Overseas expansion through subsidiary Implanet and others; research notes state that overseas business continues to grow rapidly

2.3 Industry Chain Positioning and Cost-Profit Structure

The research notes do not provide complete industry chain data such as the company's specific upstream procurement categories, supplier concentration, or the proportion of top five downstream customers. The following content is organized solely based on information appearing in the notes regarding volume-based procurement, terminal prices, M&A, and product mix. Missing fields are truthfully stated.

• The research notes do not disclose the company's specific upstream raw material/component procurement categories or supplier concentration data, and no specific cost composition can be provided.
• The notes mention that volume-based procurement of high-value spinal consumables has been fully implemented nationwide, affecting product terminal sales prices — this statement points to downstream terminal prices, not upstream procurement costs.
• The notes do not indicate whether the company has pricing power over upstream suppliers or is a price taker; this field's data is missing.
• The downstream is the orthopedic consumables terminal market, with sales affected by nationwide volume-based procurement of high-value spinal consumables. The notes state that the gross margin of spinal implant consumables of 66.40% "is mainly due to the full nationwide implementation of volume-based procurement of high-value spinal consumables during the reporting period, the company's product terminal sales prices..." (this sentence is not fully quoted in the notes).
• The notes do not disclose the combined proportion of the top five customers or customer concentration data; specific values cannot be provided. Please refer to the latest annual report for details.
• The notes mention that volume-based procurement of consumables in core orthopedic areas has all been implemented, terminal prices are relatively low, and the possibility of further significant price reductions in the future is expected to be low, with orthopedic industry procurement risks essentially cleared; import substitution in the spinal and joint sectors is a structural industry trend.
• The notes mention that volume-based procurement, anti-corruption campaigns, and other factors affected H1 performance, indicating that downstream demand and the policy environment have a direct impact on the company's short-term performance.
• The research notes do not provide absolute accounts receivable amounts, accounts receivable turnover days, prepayments, or accounts payable data, making it impossible to judge the company's bargaining position in the industry chain; this field's data is missing. Please refer to the company's latest annual report/announcements for details.
• Customer and supplier concentration data do not appear in the research notes, and the combined proportion of top five customers/suppliers cannot be provided. The report only mentions that spinal implant consumables revenue accounts for 68.30% (this proportion is a product mix proportion, not customer concentration). It is recommended to refer to the top five customer proportions disclosed in the company's latest annual report and note the source year of the data.

The research notes position Sanyou Medical as a "small but refined" domestic enterprise in the orthopedic spinal consumables field, with core profit sources from spinal implant consumables (gross margin 66.40%), positioned in the high-value consumables manufacturing segment, historically suppressed by terminal price reductions brought about by nationwide spinal procurement; the main drivers for further margin improvement are described as: procurement impact clearing (the notes state that volume-based procurement of consumables in core orthopedic areas has all been implemented, terminal prices are relatively low, and procurement risks are essentially cleared), product mix upgrading driven by significant revenue growth of new spinal products, continued rapid growth of the ultrasonic bone scalpel business, and internationalization and innovative pipeline delivery through Implanet as a vehicle. The notes do not provide sufficient data to support multi-year quantitative trends and attribution of specific gross margin/net margin figures. It is recommended to refer to the company's latest annual report data.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

Data source: 2026 semi-annual report (disclosed approximately 2026-08-25/26), 2025 annual report and earnings flash report (2026-02-27), 2025 Q3 report, Ping An Securities research report dated 2026-08-26, BOC International Securities research report dated 2026-04-30. FY2025 net profit attributable to parent on flash report basis was RMB 63.2895 million (+451.85%); non-GAAP net profit attributable to parent was RMB 49.6671 million, turning profitable (+1379.01%). 2026H1 non-GAAP net profit attributable to parent was RMB 14.2496 million (-45.24%); 2026Q2 non-GAAP was RMB 12.7546 million (-12.59%); 2026Q1 non-GAAP was RMB 1 million (-86.92%). 2025Q1-Q3 non-GAAP was RMB 49.3558 million (+1737.69%). FY2024 non-GAAP was -RMB 3.781 million. TTM (as of 2026-06-30) revenue was approximately RMB 567 million (+15.4%), net profit approximately RMB 54.2514 million (+16.9%).

The apparent profit decline in 2026H1 was mainly due to share-based payment expenses (approximately RMB 15.6076 million in 26H1), asset and credit impairment losses (approximately RMB 12.9583 million), and exchange losses (approximately RMB 6.1855 million). Under Ping An Securities' adjusted basis excluding the above factors, net profit attributable to parent was approximately RMB 62.5034 million, up 41.58% year-over-year (this "adjusted profit" is a brokerage estimate, not a company-disclosed figure). 2026H1 gross margin was 75.00%, Q2 gross margin was 76.82% (up 4.04pct QoQ); debt-to-asset ratio was 9.69%; net cash flow from operating activities was RMB 8.0359 million (prior year same period was -RMB 8.0705 million, an improvement). 2026Q1 was affected by share-based payments of RMB 7.6269 million and exchange losses of RMB 3.754 million from euro depreciation. The FY2025 earnings forecast (2026-01-29) had estimated revenue of RMB 535–562 million (+17.95%~23.90%), net profit attributable to parent of RMB 56–72.8 million (+388.29%~534.78%), and non-GAAP of RMB 43–61 million (turnaround from losses).

3.2 Earnings Forecast

Consensus source: East Money ProfitForecast, updated approximately 2026-09, number of forecasting institutions: 4, EPS constituent institutions only 3–4, coverage institutions relatively few, representing a "thin institutional consensus" with limited representativeness. Corresponding PE (trailing six-month average price basis): 2026E 42.55x, 2027E 27.37x, 2028E 20.20x. Net assets per share: 2026E RMB 6.60 (2 institutions), 2027E RMB 7.12, 2028E RMB 7.77; ROE: 2026E 4.73% (3 institutions), 2027E 6.93%, 2028E 8.67%. Individual brokerage forecasts: Zhongtai Securities (2026-05-22, Buy) EPS 2026E 0.30/2027E 0.46/2028E 0.62, net profit attributable to parent growth +56.6%/+55.6%/+34.5%; Industrial Securities (2026-05-07) EPS 0.31/0.40/0.53; BOC International Securities (2026-04-30, Buy) EPS 0.30/0.60/0.90 (closing price on report date RMB 17.69); CITIC Construction Investment (2026-05-23, Buy) EPS 0.32/0.48/0.65. Additionally, Chagu.com aggregated forecasts without attributed brokerage names stating net profit attributable to parent of RMB 113/204/286 million, EPS RMB 0.34/0.61/0.86, PE 51.6/28.6/20.4x — the attributing institution could not be cross-confirmed and the implied stock price significantly differs from the current price, judged to be an earlier report, to be used with caution. Third-party model basis (Simply Wall St, 2 analysts, updated to 2026-05-21): 2026E revenue RMB 682 million, profit RMB 101 million; 2027E revenue RMB 843 million, profit RMB 145 million; 2028E revenue RMB 1.029 billion, profit RMB 193 million; forecast EPS CAGR of approximately 39%.

3.3 Valuation Levels and Institutional Ratings

All price/valuation data are as of the 2026-09-11 close, with the current price at approximately RMB 12.8 (Sohu Securities RMB 12.81, East Money RMB 12.81, some pages showing RMB 13.33). Corresponding consensus PE: 2026E 42.55x, 2027E 27.37x, 2028E 20.20x (trailing six-month average price basis). Since 2026, mainstream research reports (BOC International, Zhongtai, Industrial Securities, CITIC Construction Investment, Ping An, etc.) mostly show "—" in the "target price" field of summary tables (target prices not publicly disclosed), with only ratings given. The historical target prices that can be found are Guotai Haitong's RMB 25.20 on 2025-09-15 (based on 2026E EPS RMB 0.45, 2026 target PE 56x) and Guotai Junan's RMB 24.97 on 2025-02-04 (based on 2026 target PE 38x), both outdated and for reference only. Rating distribution: within 3 months, 4 institutions (3 Buy + 1 Accumulate, composite rating Buy, coefficient 4.75); within 1 year, 8 institutions (5 Buy + 3 Accumulate, coefficient 4.63); at another time point, within 6 months, 7 institutions (4 Buy + 3 Accumulate, coefficient 4.57). Consensus net assets per share: 2026E RMB 6.60, 2027E RMB 7.12, 2028E RMB 7.77; ROE: 2026E 4.73%, 2027E 6.93%, 2028E 8.67%. Basic EPS for 2025 was approximately RMB 0.17 (calculated on latest share capital), and EPS for 2024 was RMB 0.05.

4. Recent News and Announcements

4.1 Target Identity Confirmation

Sanyou Medical (688085.SH), full name Shanghai Sanyou Medical Co., Ltd., Shanghai Stock Exchange STAR Market, CSRC industry C35 Special Purpose Equipment Manufacturing (medical orthopedic implant consumables). Main business is R&D, production, and sales of medical orthopedic implants and ultrasonic power devices and consumables, with core products being spinal and trauma implants, vertebroplasty consumables, and ultrasonic bone power systems (Shuimu Tianpeng). Controlling/equity participation platforms include Implanet France (spinal internal fixation, including U.S. market), Chunfeng Huayu (8i Robotics surgical robots), and Zhuiyuan Medical (cell therapy). Source: SSE official website company profile, Huaxin/Baidu Stock individual stock pages, moomoo company page (cross-confirmed).

4.2 Time Reference Note

The "latest announcements" seen in this search are as of September 12, 2026 (Announcement No. 2026-042 disclosed on September 12), based on which the "current" time of these notes is judged to be approximately mid-September 2026, with "recent" counted as June–September 2026, and retroactive to key announcements in H1 2026. Note: Dates appearing in search results (August–September 2026) coexist with historical announcements from 2025; 2025 matters are included only as background and are not listed as "recent."

4.3 FY2025 Annual Earnings Flash Report (Announcement No. 2026-007, Disclosure Date 2026-02-27)

Total operating revenue RMB 542.7925 million, +19.66% YoY; operating profit RMB 51.8071 million, +145.93%; net profit attributable to parent RMB 63.2895 million, +451.85%; non-GAAP net profit attributable to parent RMB 49.6671 million (prior year was -RMB 3.781 million, turnaround from losses); basic EPS RMB 0.19; weighted ROE 3.13%; total assets RMB 2,376.8269 million. Flash report basis, unaudited. Source: https://www.9fzt.com/detail/sh_688085_9_26b4876ff1509e7ca343fbe7d6770211.html

4.4 2026 Q1 Report (Quoted in Buyback Announcement)

2026Q1 revenue RMB 124 million, net profit attributable to parent RMB 7.06 million. Source: East Money/Caizhongshe 2026-07-21 https://finance.eastmoney.com/a/202607213815548653.html . Note: Single-source quotation, only this one instance; recommend verifying against the original quarterly report.

4.5 2026 Semi-Annual Report (Disclosure Date 2026-08-24)

Operating revenue RMB 274 million (+9.71%); net profit attributable to parent RMB 27.752 million (-24.18%); non-GAAP net profit attributable to parent RMB 14.2496 million (-45.24%); basic EPS RMB 0.08 (-20.00%); gross margin 75.00%; net operating cash flow RMB 8.04 million (prior year same period -RMB 8.0705 million); Q2 standalone revenue RMB 150 million (+12.85%), net profit attributable to parent RMB 20.6959 million (-12.96%, +193.31% QoQ). Company basis: excluding share-based payment expenses of RMB 15.6076 million, asset and credit impairment losses of RMB 12.9583 million, and exchange losses of RMB 6.1855 million, net profit attributable to parent was RMB 62.5034 million, up 41.58% year-over-year. Period-end total assets RMB 2.389 billion, net assets attributable to parent RMB 2.143 billion. Sources (multi-source cross-consistent): East Money, Securities Times, Panorama Network, Southern Finance. Note: 2025H1 net profit attributable to parent was RMB 36.6 million (per prior QM5 transfer announcement and 2025 interim report basis), consistent with the reverse-calculated value from RMB 27.752 million/-24.18%, data is self-consistent.

4.6 Share Buyback Plan (2026-07-21 to 2026-07-27)

On 2026-07-21, the 11th meeting of the 4th Board of Directors approved the buyback plan (proposed by actual controllers Michael Mingyan Liu (Liu Mingyan), Xu Nong, and David Fan (Fan Xianglong)); on 2026-07-22, the buyback plan announcement was disclosed (2026-029); on 2026-07-27, the buyback report was disclosed (2026-031). Plan highlights: buyback through centralized bidding; total funds not less than RMB 90 million and not more than RMB 180 million; funding source is own funds + special stock buyback loan (has obtained the "Loan Commitment Letter" from SPD Bank Jiading Branch); buyback price ceiling RMB 18.90/share; implementation period 2026-07-21 to 2027-01-20 (6 months); purpose is for employee stock ownership plan or equity incentive, to be cancelled if not fully used within 3 years. Based on the ceiling, estimated buyback of 4.7619–9.5238 million shares, representing 1.30%–2.60% of total share capital. Source: Securities Times, China Securities Journal, Hithink RoyalFlush.

4.7 First Buyback (2026-08-04, Announcement Date 2026-08-05)

On 2026-08-04, bought back 763,778 shares (0.21% of total share capital), transaction price RMB 12.99–13.15/share, amount RMB 9.9998 million. As of 2026-07-31, no buyback had been implemented. Source: Sina Finance announcement database.

4.8 Latest Buyback Progress (Announcement No. 2026-038, Disclosure Date 2026-09-02)

As of 2026-08-31, cumulative buyback of 3,844,812 shares, representing 1.05% of total share capital of 366,808,748 shares, transaction price range RMB 12.99–13.82/share, cumulative amount RMB 51.2793 million. Of which, in August 2026 alone, 3,844,812 shares were bought back, an increase of 0.84% from the previous disclosure. Sources (multi-source consistent): Shanghai Securities News, China Securities Journal, Sina. Implication: The company has used approximately RMB 51.28 million, approximately 57% of the plan's lower limit of RMB 90 million; ceiling of RMB 18.9 vs. actual transaction price of RMB 12.99–13.82, indicating buyback prices significantly below the price ceiling.

4.9 Total Share Capital and Buyback Special Account Holdings

As of September 2026, total share capital was 366,808,748 shares; of which the buyback special account held 5,141,763 shares, without voting rights (2026-09-11 shareholders' meeting announcement/2026-040). Note: The share capital per the FY2025 earnings flash report was 333.4625 million shares (333.46M), increasing to 366.81M by September 2026 (approximately +10%), which should be due to capital reserve conversion/profit distribution implemented during the period; the specific plan was not obtained in this search and is an unverified item.

4.10 2026 First Extraordinary Shareholders' Meeting (Announcement 2026-032, Disclosure Date 2026-08-05)

Held on 2026-08-04, approved the "Proposal on Changing the Company's Registered Address, Amending the Articles of Association, and Handling Industrial and Commercial Registration Changes" (special resolution, 99.92% in favor), 94 shareholders attended, representing 94,778,417 voting shares, accounting for 25.84%. Source: East Money announcement full text.

4.11 2026 Second Extraordinary Shareholders' Meeting (Announcement 2026-040, Disclosure Date 2026-09-12)

Held on 2026-09-11, approved the "Proposal on Reappointing the Accounting Firm"; 128 shareholders attended, representing 122,260,896 voting shares, accounting for 33.80%; presided over by Director and Senior Vice President Zheng Xiaoyi (Chairman Liu Mingyan presided over the 2026 first meeting). Source: Shanghai Securities News, East Money.

4.12 2026 Third Extraordinary Shareholders' Meeting Notice (Announcement 2026-042, Disclosure Date 2026-09-12)

Scheduled to be held on 2026-09-28, to review the "Proposal on Providing Guarantees for Controlled Companies" (approved by the 13th meeting of the 4th Board of Directors on September 11), record date 2026-09-22, on-site meeting location: No. 385 Huirong Road, Jiading District, Shanghai. Source: http://stock.stockstar.com/notice/SN2026091200000234.shtml

4.13 Equity Incentive (2025, Background)

On 2025-09-26, granted 4.782 million shares of Class II restricted stock (55 persons, RMB 11.12/share, 1.43% of total share capital); share-based payment expenses of RMB 15.6076 million were recognized in 2026H1, an important factor related to the current period's profit decline.

4.14 Major Shareholder Level (2025, Background, Not Recent)

QM5 LIMITED on 2025-09-22 proposed to transfer 6.6693 million shares (2%, original holding 14.74%) via inquiry-based transfer, with a price floor not lower than 70% of the average price of the previous 20 trading days; completed on 2025-09-27, with transferees including Guotai Fund, Taikang Asset, Hongshang Asset, etc.; on 2025-12-02, disclosed the announcement on changes in actual controllers' and concert parties' equity crossing 1% and concert party reduction results; on 2025-12-03, signed a strategic cooperation and distribution agreement with Korea Fine Biotech Co., Ltd. Source: East Money company events page, China Finance Online announcement full text, Hithink RoyalFlush. [Gap Note] This search did not obtain new shareholder reduction/increase special announcements for June–September 2026. Apart from buyback special account data, major shareholder increase/decrease dynamics within 2026 could not be cross-verified. Recommend separately checking SSE "reduction" category announcements.

4.15 Voluntary Disclosure of Robot European Installation and Clinical Cooperation (Announcement 2026-028, 2026-07-18)

Controlled company Implanet France established scientific research and clinical cooperation with CHU Amiens Picardie (Amiens-Picardy University Hospital Center) in France, conducting clinical evaluation research on Chunfeng Huayu 8i Robotics' world-first multi-arm humanoid intelligent spinal surgical robot and advancing EU CE certification; the first installation in Europe has been completed; the robot has completed scientific/clinical installations at five hospitals in North America, Asia, and Europe. Source: https://paper.cnstock.com/html/2026-07/18/content_2245855.htm

4.16 Implanet SWINGO-3D Receives U.S. FDA 510(k) Clearance (2026-08)

Implanet's SWINGO-3D lumbar interbody fusion system received U.S. FDA 510(k) clearance, and can form synergies with the JSS spinal screw-rod system. Source: BOC International Securities research report 2026-09-01, Ping An Securities research report 2026-08-26.

4.17 Chunfeng Huayu Robot Domestic Clinical Progress (2026-03)

The Chunfeng Huayu three-arm spinal surgical humanoid robot (which has passed NMPA innovative channel approval) completed the world's first registered clinical trial enrollment at Nanjing Drum Tower Hospital, and is currently conducting clinical trials at 3 tertiary hospitals in China.

4.18 Cell Therapy Layout

With own funds of RMB 20 million, increased capital in Zhuiyuan Medical (intervertebral disc degeneration repair, FibroCell-001 allogeneic human fibroblast injection under development); in June 2026, Zhuiyuan Medical launched a new round of capital increase, with Sanyou Medical's three actual controllers Xu Nong, Liu Mingyan, and Fan Xianglong participating alongside Qiming Venture Partners (total subscription of RMB 25 million, single-source figure, needs verification).

4.19 2026H1 Operating Data (Semi-Annual Report Basis)

Implanet France revenue EUR 7.134 million (+22.81%), of which U.S. market revenue +54.42%; Q2 Implanet revenue +27.02% YoY, +35.45% QoQ; Shuimu Tianpeng standalone consolidated revenue RMB 74.5064 million, non-GAAP net profit attributable to parent RMB 25.9048 million.

4.20 Other Background Announcements

2025-10-10 disclosed "Announcement on Receiving Government Subsidies"; 2025-08-29 "bone filling capsule bag" obtained medical device registration certificate.

4.21 Policy/Regulatory Related (Affecting Core Business, Policy News Actively Cited by the Company)

In January 2026, the National Healthcare Security Administration issued the "Guidelines for Establishing Price Items for Surgical and Therapeutic Auxiliary Operation Medical Services (Trial)," providing pricing/pricing policy support for the admission of consumables such as ultrasonic bone scalpels into hospitals; the company states that with implementation across provinces, this is expected to increase the coverage rate of ultrasonic bone scalpel consumables. In July 2026, the National Healthcare Security Administration included approximately 170 new technology items such as surgical robots into price items (according to Jingguang Zhixun transcription, needs verification against official documents). Industry level: in the second round of spinal procurement renewal, the company plans to include some high-end Zeus products in procurement volume reporting to increase share (Ping An Securities research report basis). In 2026H1, China's surgical robot exports amounted to RMB 480 million, +3.3x year-over-year, with export markets expanding from 23 to 49 countries (Panorama Network citing industry data, single source).

4.22 Institutional Ratings/Earnings Forecasts (For "Recent News" Reference Only, Not Official Disclosure)

BOC International Securities (Liu Enyang, Su Xue'er), 2026-09-01, "Buy," title "Profit under pressure, internationalization business continues to accelerate." Source: https://data.eastmoney.com/report/zw_stock.jshtml?encodeUrl=nvq1k4WVF4uNNh0uW2oTTYR+Y8bxCeHx4RLJpvxhx7o= . Ping An Securities (Ye Yin, Ni Yidao, Pei Xiaopeng), 2026-08-26, "Recommended," lowered 2026–2028 net profit attributable to parent forecasts to RMB 100/129/174 million (previously 2026–2027 were RMB 160/257 million). Source: http://stockfinance.sina.cn/stock/go.php/paper/reportid/841102042316/index.phtml . Note: The above are individual forecasts from two brokerages, not consensus estimates from multiple brokerages; Hithink RoyalFlush consensus data was not obtained in this search.

4.23 Uncertainties/Limitations to Note

1) Time reference: Based on the latest announcement retrieved (2026-09-12), the current time is inferred to be mid-September 2026; if the actual search time differs, please adjust the "recent" window accordingly. 2) Buyback amounts are on a basis "excluding stamp duty and brokerage commissions," and RMB 180 million is a ceiling, not a committed execution amount; subsequent September buyback progress announcements (expected to be disclosed in early October) are not included. 3) 2026Q1 revenue of RMB 124 million/net profit attributable to parent of RMB 7.06 million is from a single source only (Caizhongshe citation), not cross-verified by a second source. 4) The cause of share capital increasing from 333.46M at end-2025 to 366.81M in September 2026 (number/ratio of capital reserve conversions) has not been verified. 5) Whether there are other announcements on shareholder reductions/increases, pledges, litigation, inquiries, etc., during June–September 2026 was not found in this search; this is an information gap and should not be treated as "none." 6) Some data comes from the "excluding items" basis in the company's semi-annual report/voluntary disclosures (RMB 62.5034 million +41.58%), which is a company-adjusted non-GAAP metric and should be presented separately from the apparent net profit attributable to parent of RMB 27.752 million (-24.18%). 7) Stock price/market cap: Sina page shows Sanyou Medical at RMB 13.270 (+0.14, +1.07%), but the timestamp of this price widget is unclear; for reference only. Based on 366.81M total share capital, total market cap is approximately RMB 4.87 billion (estimated value, not official). 8) Details such as "Zhuiyuan Medical's new round of capital increase in June 2026, with actual controllers subscribing a total of RMB 25 million" are from a single source such as Panorama Network only; figures need to be verified against the original company announcement.

4.24 Main Source List (Traceable)

SSE company overview: http://www.sse.com.cn/star/en/marketdata/snapshot/c/5537599.shtml ; East Money announcements/events page: https://emweb.securities.eastmoney.com/CompanyBigNews/Index?type=soft&code=SH688085 ; China Finance Online announcement full text list: https://gg.cfi.cn/ggqw/93421/688085.html ; FY2025 earnings flash report: https://www.9fzt.com/detail/sh_688085_9_26b4876ff1509e7ca343fbe7d6770211.html ; 2026 semi-annual report coverage: https://finance.eastmoney.com/a/202608243851407172.html , https://stcn.com/article/detail/4115490.html ; Buyback plan (2026-07-21/27): https://stcn.com/article/detail/4032358.html , http://yuanchuang.10jqka.com.cn/20260727/c678438425.shtml ; Buyback progress (2026-09-02, Announcement 2026-038): https://paper.cnstock.com/html/2026-09/02/content_2264450.htm ; 2026 second extraordinary shareholders' meeting (2026-09-12): https://paper.cnstock.com/html/2026-09/12/content_2268204.htm ; Robot European installation voluntary disclosure (2026-07-18): https://paper.cnstock.com/html/2026-07/18/content_2245855.htm ; Research reports: BOC International Securities 2026-09-01 (eastmoney report link), Ping An Securities 2026-08-26 (sina stockfinance link).

5. Stock Price Trend and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

Sanyou Medical's stock price has declined continuously since the staged rebound high of RMB 13.70 on September 4, 2026, closing at RMB 12.81 on September 11 and breaking below the RMB 13.00 integer level, with an intraday low of RMB 12.71. The current price is below MA5, MA10, MA20, and the lower Bollinger Band, MACD is below the zero line, and RSI is generally weak but not yet at extreme oversold levels, indicating a weak short-term technical pattern. In terms of funds, institutional funds showed a slight net inflow on September 10, but over the past 10 trading days, institutional funds recorded a cumulative net outflow of approximately RMB 17.36 million, without forming a continuous stable net inflow trend; September 11 turnover was approximately RMB 20.5 million with a turnover rate of approximately 0.46%, representing a relatively low-volume decline recently. In the short term, key observations include the support situation in the RMB 12.70–12.95 area, and whether a rebound can reclaim RMB 13.15–13.35 with volume confirmation.

5.3 Short-Term Outlook (Next Week, Scenario Analysis, For Reference Only)

⚠️ Risk Warning: The following content is solely a subjective scenario analysis based on publicly available market data, technical indicators, and trading activity. It does not constitute investment advice and does not represent a deterministic prediction of future stock price movements.

① Key Technical Levels

② Next Week Scenarios (Subjective Weighting, Not Statistical Probability)

• Range-bound consolidation (relatively higher weight, approximately 60%; this weight is a subjective heuristic judgment based on current technical and fund structure, not statistical probability.): Price range approximately RMB 12.70–13.35. Trigger conditions include: stock price stabilizes in the RMB 12.70–12.95 area, volume remains at recent normal levels without continuous volume-driven declines, MACD histogram negative values no longer significantly expand, and no significant systemic decline in the pharmaceutical/biotech or medical device sector. If this scenario materializes, the stock price may fluctuate around RMB 12.80–13.30, with rebounds first facing resistance at RMB 13.15–13.35.
• Weaker downside (moderate weight; this weight is a subjective judgment, not statistical probability.): Price range approximately RMB 12.00–12.70. Trigger conditions include: volume breakout below RMB 12.70, daily turnover continuously above recent normal levels with closing prices near intraday lows, pharmaceutical/biotech sector continuing to underperform the broader market, and institutional funds showing consecutive large net outflows. If RMB 12.70 is breached, the next observation area is RMB 12.00–12.30, and vigilance is needed for a technical correction evolving into a new downward wave.
• Rebound strengthening (lower weight but not impossible; this weight is a subjective judgment, not statistical probability.): Price range approximately RMB 13.30–13.80. Trigger conditions include: stock price reclaiming RMB 12.95–13.05, then recovering RMB 13.15–13.35; turnover significantly increasing, with at least one consecutive trading day above the recent normal level of approximately RMB 30 million; MACD histogram turning from negative to positive or RSI6 reclaiming above 50; medical device sector strengthening in tandem, or the company releasing positive announcements that could change short-term expectations. Only a volume breakout above RMB 13.60–13.70 would be considered a significant strengthening of short-term rebound momentum; otherwise, it is more likely an oversold bounce.

③ Fund and Liquidity Background

As of September 11, 2026, turnover estimated from volume was approximately RMB 20.5 million, with a turnover rate of approximately 0.46%; from September 1 to September 11, 2026, turnover was roughly in the RMB 20–45 million range. Total market cap is approximately RMB 4.7 billion, but average daily turnover is relatively low; if sudden news or sector anomalies occur, bid-ask spreads and price slippage may widen, and short-term price trends require volume confirmation. In terms of shareholder structure, the latest detailed top ten tradable shareholder data is as of March 31, 2026, with the top ten tradable shareholders holding approximately 47.57% in total; as of June 30, 2026, the total number of shareholders was 10,001, an increase of approximately 6.29% from 9,409 as of March 31, 2026. The top ten tradable shareholders include institutional investors such as social security funds, public funds, and private funds; platform statistics show institutional shareholders collectively holding approximately 9.11% of tradable shares, but this figure is on a platform statistical basis and does not provide a complete real-time shareholder register. The current structure reflects relatively concentrated holdings by controlling shareholders, management, and related natural persons, while the increase in shareholder numbers may indicate some dispersion of holdings compared to Q1; the above shareholder data has a quarterly lag and may differ from the real-time structure as of September 11, 2026, and cannot be directly regarded as real-time holdings. In actual trading, a lower turnover rate means liquidity mainly depends on market trading funds, and the order book may be relatively thin during anomalies, potentially increasing price slippage risk.

Volume confirmation signals to monitor: if subsequent daily turnover continuously expands to approximately RMB 35–45 million or more, while the stock price reclaims the RMB 13.15–13.35 area, this can be regarded as an observation signal of improved short-term support; if volume expands but the stock price continues to close below RMB 12.70, this is more indicative of fund liquidation or increased selling pressure.

④ Key Points to Watch (Observation Ideas Only, Not Trading Instructions)

• Observe whether the stock price can stabilize in the RMB 12.70–12.95 area; observation idea, not trading instruction.
• Observe whether RMB 13.15–13.35 can be reclaimed; this area corresponds to the Bollinger middle band, MA20, and recent dense trading area; observation idea, not trading instruction.
• If the stock price rebounds to RMB 13.50–13.70, observe whether it is accompanied by significantly increased turnover; observation idea, not trading instruction.
• If daily turnover continuously reaches approximately RMB 35–45 million or more, and the stock price simultaneously reclaims RMB 13.15–13.35, this can serve as an observation signal of improved price-volume relationship; observation idea, not trading instruction.

The above scenario analysis is based on September 11, 2026 closing data and historical prices and technical indicator calculations. Short-term stock prices are also affected by multiple factors including news, fund flows, and the broader market environment. Technical indicators themselves have lag and limitations, do not guarantee actual future movements, and do not constitute buy or sell recommendations. Please make independent judgments based on the latest market information and bear investment risks yourself.

6. Industry Landscape and Competitor Analysis

6.1 Industry Status

The research notes indicate that the company operates in the orthopedic high-value consumables industry (primarily spinal implant consumables), extending to active devices such as ultrasonic bone scalpels and spinal surgical robots. The core industry variable is orthopedic volume-based procurement: the notes state that after nearly 3 years, volume-based procurement of consumables in core orthopedic areas has all been implemented, terminal prices are relatively low, and the possibility of further significant price reductions in the future is expected to be low. Overall, orthopedic industry procurement risks are essentially cleared, and import substitution in the spinal and joint sectors is a structural trend.

6.2 Competitive Landscape

• Orthopedic procurement: The notes state that after nearly 3 years, volume-based procurement of consumables in core orthopedic areas has all been implemented, terminal prices are relatively low, further significant price reductions are unlikely, and industry procurement risks are essentially cleared.
• Import substitution: The notes highlight the import substitution trend in the spinal and joint sectors (original text: "in the spinal and joint sectors, import substitution..." sentence not fully included).
• Ultrasonic bone scalpel: The notes state that Shuimu Tianpeng is a well-known domestic ultrasonic bone scalpel company. Sanyou Medical achieved 100% ownership after acquiring its remaining equity, and some research reports call it a domestic leader in ultrasonic bone scalpels.
• Internationalization/surgical robots: The notes mention that subsidiary Implanet completed the first multi-arm spinal surgical robot installation in Europe, constituting an internationalization and innovation pipeline direction.
• Demand-side disruptions: The notes mention that procurement, anti-corruption campaigns, and other factors affected H1 performance.

6.3 Main Competitors

The research notes do not provide direct comparable data between the company and other listed peers in terms of revenue, gross margin, net margin, etc., so a quantitative horizontal comparison cannot be formed; the comparable information available in the notes is mainly qualitative judgment: orthopedic procurement risks essentially cleared, import substitution advancing in the spinal and joint sectors, the company's own ultrasonic bone scalpel business continuing to grow rapidly, and overseas business growing rapidly. Specific peer benchmarking company names and financial data are missing from the research notes; it is recommended to refer to the latest annual report and brokerage comparable company tables.

7. Risk Warnings

• Spinal implant consumables revenue accounts for 68.30%, indicating high dependence on a single core business. Although the notes consider orthopedic procurement risks essentially cleared, terminal prices for spinal consumables are already relatively low. If renewal bidding, volume reporting, or terminal competition further压低 prices, it may pressure this business's revenue and gross margin.
• In H1 2026, net profit attributable to parent declined 24.18% year-over-year, and non-GAAP net profit attributable to parent declined 45.24% year-over-year; share-based payment expenses, asset and credit impairment losses, and exchange losses collectively caused significant disturbance to current period profit. If related expenses or impairments continue to occur, adjusted profit growth may not fully translate into reported profit.
• The company's goodwill is approximately RMB 346 million, and the Shuimu Tianpeng acquisition as well as overseas and robotics businesses are still in expansion or commercialization advancement stages. If acquired businesses' profitability falls short of expectations or integration synergies underperform, there is risk of goodwill or related asset impairment.
• Although the ultrasonic bone scalpel has become an important growth direction for the company, its revenue ramp-up still depends on the implementation of provincial pricing policies, hospital admission coverage, and clinical promotion; if the progress of pricing item implementation or terminal promotion falls short of expectations, Shuimu Tianpeng's high growth may slow.
• The robot business's currently disclosed progress mainly includes the first European installation, clinical cooperation, domestic clinical trials, and advancing EU CE certification; commercial revenue scale and profit contribution are not yet clear. If certification, clinical evaluation, or hospital procurement progress falls short of expectations, the robot's support for company performance may be below market expectations.
• Overseas business involves Implanet France, the U.S. market, and EUR and other foreign currency settlements. In H1 2026, exchange losses of RMB 6.1855 million already occurred, and Q1 disclosed the impact of euro depreciation. Exchange rate fluctuations or overseas regulatory and market expansion uncertainties may continue to affect profit and cash flow.
• The company's future earnings forecasts have relatively few covering institutions, and there are differences between 2026–2028 consensus estimates and different brokerage forecasts; the current stock price corresponds to a consensus 2026 PE of approximately 42.55x. If revenue, profit, or ultrasonic bone scalpel and overseas business delivery falls short of expectations, valuation digestion pressure may increase.
• As of September 11, 2026, the stock price is below multiple short-term moving averages and the lower Bollinger Band, institutional funds recorded a cumulative net outflow of approximately RMB 17.36 million over the past 10 trading days, daily turnover was approximately RMB 20.5 million with a turnover rate of approximately 0.46%. Given low trading activity, if volume breaks below support near RMB 12.70, price volatility and liquidity risks may increase.

8. Conclusion and Outlook

The company's fundamentals are in a stage of recovery from the spinal procurement shock and transition toward multi-business drivers. Spinal consumables remain the revenue and profit foundation, and industry procurement risks are considered essentially cleared, but terminal prices are at relatively low levels; full ownership of the ultrasonic bone scalpel, Implanet overseas revenue growth, U.S. market expansion, and robot product installations provide potential support for revenue mix upgrading and internationalization expansion. Q2 2026 revenue growth accelerated to 12.85% year-over-year, and net profit attributable to parent grew 193.31% quarter-over-quarter, indicating signs of operational improvement.

The sustainability of profit growth still depends on recovery of the core spinal business, ultrasonic bone scalpel ramp-up, overseas business expansion, and commercialization progress of robots and innovative pipelines. In H1 2026, apparent profit still declined year-over-year, and share-based payments, impairments, and exchange factors caused significant profit disturbance; market forecasts are relatively optimistic about future profit growth, but Ping An Securities has already lowered its 2026–2028 net profit attributable to parent forecasts to RMB 100 million, RMB 129 million, and RMB 174 million, indicating that there are still divergences on earnings delivery.

From a trading perspective, the stock price is in the lower part of the 52-week range, and no clear technical repair signal has yet appeared in the short term. RMB 12.70–12.95 is the recent support observation area, and RMB 13.15–13.35 and RMB 13.50–13.70 are rebound resistance areas. The company has initiated a share buyback of RMB 90 million to RMB 180 million, with cumulative buyback amount of approximately RMB 51.2793 million as of end-August, but the impact of the buyback on price and market sentiment still needs to be judged in conjunction with subsequent volume, performance, and business progress.

Data Sources

• Sanyou Medical (688085)_Stock Overview_Stock Price_Real-time Quotes_Charts_News_Stock Commentary_Financial Reports_FinScope-AI Makes Investing Simpler
• 688084 Jingpin Tezhuang
• Sanyou Medical Listed Company Information - Sanyou Medical Listed Company Information
• 688835 Gaokai Technology
• 688610 Aike Optoelectronics
• Sanyou Medical (688085) What Does the Company Do
• Sanyou Medical (688085) September 10 Institutional Funds Net Buy RMB 2.3837 Million - Securities Star
• 2025 Shanghai Sanyou Medical Co., Ltd. Interim Report_Pharnexcloud - Insight into Market Landscape
• 688085 | SHANGHAI STOCK EXCHANGE - Brief Introduction
• Shanghai Sanyou Medical Co., Ltd: Actionnaires Dirigeants et Profil Société | 688085 | CNE1000040J7 | Zonebourse Suisse - 178fce757ad334d
• Sanyou Medical (688085) What Does the Company Do
• 688135 Liyang Chip - During the reporting period, the company adhered to market orientation, and based on market development trends and the company's strategic layout direction, steadily invested in mid-to-high-end integrated circuit testing capacity to meet the testing capacity needs of existing and potential customers
• פרופיל מניית Shanghai Sanyou Medical Co - Investing.com
• Sanyou Medical: Subsidiary Implanet Completes First Multi-Arm Spinal Surgical Robot Installation in Europe - Economic Information Network _ Xinhua News Agency "Economic Information Daily" Official Website
• Sanyou Medical (688085): Spinal Business Steadily Recovering, Bullish on Overseas Expansion and Accelerated Delivery of Innovative Pipeline
• In-DepthCompanySanyou Medical (688085): Profit Affected by Short-Term Factors, Overseas Business Continues to Grow Rapidly
• Profit Affected by Short-Term Factors, Overseas Business Continues to Grow Rapidly
• In-DepthCompanySanyou Medical (688085): Profit Affected by Short-Term Factors, Overseas Business Continues to Grow Rapidly
• Sanyou Medical: 2025 Net Profit Grew 450.20%, Overseas Expansion + Ultrasonic Bone Scalpel Build a Global Orthopedic Platform
• Earnings Express | Sanyou Medical (688085) FY2025 Net Profit Surged 4.5x, Non-GAAP Turned Profitable, but Goodwill as High as RMB 346 Million
• BOC International Securities: Gives Sanyou Medical Buy Rating - Bank of China International Securities Co., Ltd. recently conducted research on Sanyou Medical and published a research report "Profit Affected by Short-Term Factors, Overseas Business Continues to Grow Rapidly," giving Sanyou Medical a Buy rating
• Profit Affected by Short-Term Factors, Overseas Business Continues to Grow Rapidly - - Homepage
• Sanyou Medical (688085): Profit Affected by Short-Term Factors, Overseas Business Continues to Grow Rapidly - chaguwang
• Sanyou Medical: Proposed Full Ownership of Shuimu Tianpeng to Further Strengthen Strategic Synergies, Trading Resumes on the 7th
• Sanyou Medical: Proposed Acquisition of Controlled Subsidiary to Help Improve Listed Company Profitability
• Tianfeng Securities: Gives Sanyou Medical Buy Rating
• Shuimu Tianpeng Acquisition Announcement Published, Bullish on the Company's Future Growth
• In-DepthCompanySanyou Medical (688085): Shuimu Tianpeng Acquisition Announcement Published, Bullish on the Company's Future Growth
• Sanyou Medical Proposed Acquisition of Shuimu Tianpeng Remaining Equity
• Sanyou Medical (688085): Proposed Additional Issuance to Acquire Shuimu Tianpeng Remaining Equity Approved by Exchange, Doubling Down on Active Device Segment
• Well-Known Domestic Ultrasonic Bone Scalpel Company, 100% Acquired
• Sanyou Medical (688085) Initiation Report: Orthopedic Procurement Impact Clearing, Ultrasonic Bone Scalpel Business Thriving
• Pharmaceutical Reports_Pharmaceutical Industry Analysis Reports_Clinical Research Analysis Report Downloads_Page 8214-Pharnexcloud Consulting - Sanyou Medical (688085) Event: On January 3, the company announced a proposal to acquire the remaining 48.1846% equity of Shuimu Tianpeng through share issuance and cash payment, directly and indirectly, and raise matching funds, with a transaction price of RMB 415.6757 million, holding 100% equity of Shuimu Tianpeng through direct and indirect means
• Sanyou Medical - During the reporting period, the company's main product spinal implant consumables achieved operating revenue of RMB 309.0714 million, accounting for 68.30% of total operating revenue, with operating cost of RMB 103.8342 million and gross margin of 66.40%, mainly due to the full nationwide implementation of volume-based procurement of high-value spinal consumables during the reporting period, the company's product terminal sales prices...
• Sanyou Medical (688085): Spinal Consumables Accelerating Volume Ramp-Up, Ultrasonic Bone Scalpel Continuing High Growth
• Pharmaceutical Reports_Pharmaceutical Industry Analysis Reports_Clinical Research Analysis Report Downloads_Page 8778-Pharnexcloud Consulting - Sanyou Medical (688085) Report Highlights: Sector procurement impact gradually clearing, new spinal product revenue growth significant. After nearly 3 years of procurement, volume-based procurement of consumables in core orthopedic areas has all been implemented, terminal prices are relatively low, we expect the possibility of further significant price reductions in the future to be low, and overall, orthopedic industry procurement risks are essentially cleared, in the spinal and joint sectors import substitution...
• Sanyou Medical Development Prospects: Spinal Procurement Clearing, Performance Bottoming, Ultrasonic Bone Scalpel High Growth + Internationalization Opening Second Curve - Three Pijiang Report — Curated Whole-Industry Research Report Sharing and Download Platform, Your Exclusive Industry Think Tank
• Sanyou Medical (688085): Procurement, Anti-Corruption Affecting H1 Performance, Ultrasonic Bone Scalpel Promotion and Internationalization Strategy Progressing Smoothly
• Sanyou Medical Spinal Procurement Clearing: Revenue Decline Narrowed to 1.5%, 2025 Ushers in Performance Inflection Point | Hua'an Securities
• 2026 Sanyou Medical (688085.SH) Company Research Report: Spinal Procurement Clearing, Ultrasonic Bone Scalpel and Spinal Robot Product Matrix and...